After almost 20 years of work, [the implementation of EU HTA legislation] will finally become a reality in 2025 with joint work on scientific consultations, clinical…
In Conversation
It is now once more an attractive proposition to invest in Greek manufacturing and regain some of the momentum lost in the previous decade
Our view is that all stakeholders – not just payers – have responsibility for ensuring access, meaning that building on strong collaborations and public-private partnerships will be…
Our whole-of-society approach to healthcare aims to maximize health and well-being by addressing people's needs as early as possible, from health promotion and disease prevention to…
The hard times are behind us and we can look forward to a more hopeful future. We are better positioned and prepared than in the past
There is a lot to be optimistic about in Greece. For example, the implementation of a digital app and vaccination certificate during COVID-19 worked very well.…
Two LatAm countries – Colombia and Mexico – are [MSD's] top clinical trial patient enrollers worldwide, and LatAm makes up approximately 15 percent of our total…
What we are trying to do is to get new drugs that are patented into low- and middle-income countries as soon as possible – trying to…
The industry needs to think ethical by design. Ethics are difficult to sprinkle on top once a technology has already been developed, they need to be…
A third point of attraction was the Greek ecosystem which although emerging from a recession has a great appetite for fast access to new treatments. The…
Despite the uncertainty of [LatAm] markets - due to inflation, political issues or even social ones - these challenges are what make us stronger and perform…
Healthcare sustainability depends on breaking down silos, bringing all stakeholders together with the patient at the centre to deliver mutual benefit. If the patient – who…
